Caladrius Biosciences (NASDAQ:CLBS) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of Caladrius Biosciences (NASDAQ:CLBS) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

A number of other brokerages have also recently issued reports on CLBS. ValuEngine cut Caladrius Biosciences from a buy rating to a hold rating in a report on Wednesday, May 1st. Chardan Capital restated a buy rating and set a $6.00 target price on shares of Caladrius Biosciences in a report on Sunday, May 12th. Dawson James restated a buy rating on shares of Caladrius Biosciences in a report on Wednesday, February 27th. Finally, WBB Securities started coverage on Caladrius Biosciences in a report on Tuesday, May 14th. They set a speculative buy rating and a $6.75 target price on the stock. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $9.25.

Shares of CLBS opened at $2.86 on Tuesday. Caladrius Biosciences has a 1 year low of $2.65 and a 1 year high of $11.65.

Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.05). As a group, research analysts predict that Caladrius Biosciences will post -1.65 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of CLBS. Morgan Stanley boosted its holdings in Caladrius Biosciences by 218.6% during the first quarter. Morgan Stanley now owns 6,996 shares of the biotechnology company’s stock worth $25,000 after buying an additional 4,800 shares during the last quarter. Wesbanco Bank Inc. bought a new position in Caladrius Biosciences during the first quarter worth about $36,000. Summit Trail Advisors LLC bought a new position in Caladrius Biosciences during the first quarter worth about $64,000. Renaissance Technologies LLC boosted its holdings in Caladrius Biosciences by 6.9% during the first quarter. Renaissance Technologies LLC now owns 315,348 shares of the biotechnology company’s stock worth $1,142,000 after buying an additional 20,253 shares during the last quarter. Finally, Vanguard Group Inc lifted its holdings in shares of Caladrius Biosciences by 2.9% during the 3rd quarter. Vanguard Group Inc now owns 202,568 shares of the biotechnology company’s stock valued at $1,196,000 after purchasing an additional 5,700 shares in the last quarter. Hedge funds and other institutional investors own 7.59% of the company’s stock.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Featured Story: How to calculate compound interest

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.